“..By vacating the DEA’s delicensing order, the court has reinforced the boundaries of the Administrative Procedure Act (APA), signaling that agency deference does not grant a license to redefine clinical practice through internal, “invented” interpretations of medical authority..”
youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, IN THE SPIRIT OF WALTER R. CLEMENT MS., MBA., BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., IN THE SPIRIT OF REV. C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF WILLIE GUINYARD BS., IN THE SPIRIT OF ERLIN CLEMENT SR., JOSEPH WEBSTER MD., MBA, IN THE SPIRIT OF RICHARD KAUL, MD., BEVERLY C. PRINCE MD., FACS., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, ADRIENNE EDMUNDSON, IN THE SPIRIT OF WALTER F. WRENN III, MD., ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NDJOU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
NEUMANNS’ PHARMACY: A FEDERAL COURT APPEALS SMACKDOWN !!!
‘The Limits of Corresponding Responsibility: Dismantling DEA Overreach in Pharmacy Practice,’ along with a brief description of a strategic defense for independent compounding pharmacies and legal validation.
*A LEGAL FICTION*
OF D.E.A. AND THE FATAL MISDIRECTION OF OUR STATE BOARDS OF PHARMACY
THE NEUMANN RULING
AND THE PHARMACIST LEGAL TIGHT ROPE
The Judicial Pivot in Controlled Substances Regulation
Legal Analysis: Neumann’s Pharmacy vs. DEA and the Redefinition of “Usual Course of Professional Practice”
Introduction
Recent judicial developments, specifically the Fifth Circuit’s decision in Neumann’s Pharmacy v. DEA, have established critical protections for pharmacists by requiring the government to prove actual knowledge of illegitimacy rather than relying on “red flags” or statistical anomalies. This ruling challenges the DEA’s expansive enforcement tactics, which critics argue criminalize professional medical judgment and unfairly penalize the dispensing of high-dose pain medications.
The text highlights how previous administrative actions, such as the deregistration of Norman Clement’s Pronto Pharmacy, LLC, Tampa, Florida, were upheld despite claims of judicial nonfeasance and the improper federal intrusion into state medical regulation. Beyond the legal framework, healthcare advocates emphasize that pain is a subjective and emotional experience that cannot always be measured through objective diagnostic imaging.
The ruling delivered by the U.S. Court of Appeals for the Fifth Circuit in Neumanns Pharmacy of Tallulah v. U.S. DEA (February 13, 2026) marks a significant jurisprudential shift in the landscape of administrative law. This decision serves as a decisive check on the extra-statutory expansion of federal agencies’ authority, specifically challenging the Drug Enforcement Administration’s (DEA) long-standing autonomy in setting medical standards.
Pharmacies outlining three key points
By vacating the DEA’s delicensing order, the court has reinforced the boundaries of the Administrative Procedure Act (APA), signaling that agency deference does not grant a license to redefine clinical practice through internal, “invented” interpretations of medical authority.
The primary objective of this review is to analyze how the Neumanns decision exposes the legal fragility of the DEA’s “usual course of professional practice” standard—a framework previously utilized to discipline providers with unchecked administrative latitude. This judicial correction occurs against a backdrop of deeply flawed regulatory policy, necessitating a transition toward an evidence-based approach to the American opioid crisis.
Consequently, treating prescriptions with suspicion based on automated data ignores the complexity of human suffering and undermines the essential clinician-patient relationship.
The Empirical Disconnect: Regulatory Policy vs. Clinical Reality
The strategic alignment of public health policy with empirical data is a prerequisite for a functional healthcare system. However, the current regulatory environment is characterized by a systemic disconnect where policies are founded upon what Dr. Richard Lawhern identifies as “misinformation and fraud.”
This misinformation is not merely accidental; it is actively promoted by financially self-interested academicians and senior staff within multiple federal healthcare and law enforcement agencies. This regulatory capture has fostered a “politically pre-determined narrative” that contradicts the agencies’ own data, particularly regarding the treatment of severe acute and chronic pain.
Politically Pre-determined Narrative vs. Evidence-Based Reality
| Politically Pre-determined Narrative (CDC, FDA, DEA) | Evidence-Based Reality (Independent Analysis & CDC Data) |
| The “opioid crisis” is a direct result of physician prescribing habits within the doctor-patient relationship. | The crisis is driven by illegally manufactured street drugs and diverted substances, not legitimate medical prescriptions. |
| Aggressive prescription volume reduction is the primary mechanism for reducing overdose mortality. | Restrictive policies have failed to curb overdoses while triggering a surge in patient suicides and “medical collapse.” |
| Agency-defined “usual course of professional practice” constitutes a valid legal standard for prosecution. | The DEA has utilized invented interpretations of “usual practice” that deviate from the literal statutory text and applicable law. |
| Regulatory surveillance protects public health by identifying “pill mills” and high-risk prescribers. | Analysis of 35 million medical records suggests that surveillance has facilitated “malicious and unfounded” prosecution of law-abiding providers. |
The implications of this jurisdictional shift are profound. By misidentifying the source of the crisis, federal agencies have systematically wrecked the practice of pain medicine across the United States. Rather than addressing the illicit market, regulatory pressure has destabilized the infrastructure of chronic pain management, transforming a public health challenge into a humanitarian crisis. This failure is not merely a policy error but is facilitated by specific legal mechanisms that the Neumanns decision has now called into question.
IN NEUMANN FIFTH CIRCUIT RULED
Case Review: Neumanns Pharmacy of Tallulah vs. US DEA
The Fifth Circuit’s February 13, 2026, decision is a landmark ruling that delegitimizes the DEA’s standard operating procedures for pharmacy delicensing. Central to the court’s holding was a “Grammar Lesson” delivered to the agency: the court roundly rejected the DEA’s attempt to expand its authority through a linguistic re-engineering of the law.
Specifically, the court held the DEA to the literal, statutory text of the Controlled Substances Act, rather than allowing the agency to enforce an “invented” standard that would bypass the plain-meaning rule. The court identified several critical differentiators where the DEA’s internal interpretations diverged from applicable law:
- Extra-Statutory Redefinition of “Usual Practice”: The DEA attempted to enforce a definition of “usual course of professional practice” that the court found was unsupported by statute.
- The “Corresponding Responsibility” Trap: The court rejected the DEA’s expanded interpretation of a pharmacist’s responsibility, which the agency had used to manufacture “red flags” and justify delicensing even when medications were legitimately prescribed.
- Adherence to the Plain Meaning Rule: The ruling emphasized that administrative agencies cannot “invent” standards to encompass broader regulatory goals if those standards do not reflect the text of the law as written.
The significance of this ruling extends far beyond a single pharmacy in Tallulah. By declaring the DEA’s interpretations legally invalid, the court has undermined the foundation of hundreds of previous convictions. This suggests that a significant number of healthcare providers may have been subject to “false imprisonments” based on standards that never actually existed in law. Consequently, this necessitates a wave of habeas corpus petitions and civil rights litigation to address the systemic misapplication of justice against the medical community.
THE PHARMACIST DILEMMA, DECEMBER 19, 2025
Anatomy of Malicious Prosecution in Healthcare
The pattern of “malicious and unfounded prosecution” directed at the medical community by the Department of Justice (DOJ) and the DEA represents a grave departure from the mission of public safety. This pattern is increasingly characterized by a “surveillance by algorithms” approach—what some might describe as a world “watched over by machines of loving grace”—where automated systems flag providers based on volume rather than clinical outcomes.
Evidence supporting the claim of systemic malicious prosecution includes:
- Comprehensive Data Analysis: An exhaustive review of the medical records of over 35 million commercially insured and Veterans Administration patients.
- Longitudinal Clearance: Data following these patients for up to six years showing no evidence of criminal intent or medical malpractice by the prosecuted providers.
- Agency Contradiction: The reliance on prosecutions even when the CDC’s own data demonstrates that the “opioid crisis” is not a product of legitimate clinical encounters.
Clinical Consequences: The Crisis of Under-Prescribing
The “harm done by under-prescribing” has become a critical, yet often ignored, metric for evaluating the success of federal regulatory policy. When agencies prioritize the reduction of prescription numbers over the survival of patients, the result is a systemic failure of clinical medicine.
The human toll described in the source context is quantified by a “unanimous clinical consensus” that stands in direct opposition to fraudulent regulatory mandates.
- Patient Mortality: The direct link between restrictive opioid policies and deaths by suicide is undeniable. Patients suffering from severe acute or chronic pain find themselves abandoned by a system that has been intimidated into inaction.
- Medical Collapse: The systemic failure of hospitals and clinical practices to provide adequate pain relief has led to a collapse in quality of care, forcing millions into a state of permanent agony.
- Institutional Acknowledgement: This crisis is acknowledged by the American Medical Association (AMA) and multiple nationally prominent medical associations representing over 600,000 physicians and medical students.
The current policy is not merely misguided; it is “knowingly” harmful. By ignoring the data and the warnings of the medical community, regulatory agencies are participating in a regime that is killing patients in large numbers. The transition from clinical care to regulatory compliance has created a void where effective pain management once existed.
Strategic Conclusion: Re-establishing the Boundaries of Authority
The legal victory in Neumann’s Pharmacy vs. DEA is a vital catalyst for a data-driven overhaul of opioid regulation. It serves as a necessary reminder that administrative agencies do not possess the authority to “invent” law or redefine medical practice through creative interpretation. The protection of the “usual course of professional practice” is not a mere legal technicality; it is a fundamental safeguard against the “Anti-Trinity” of isolation, agony, and the abandonment of 50 million souls who suffer under the current regulatory regime.
The Neumanns ruling provides the framework for re-establishing the boundaries of agency authority. Judicial oversight is the only remaining mechanism capable of correcting the fatal misdirection of U.S. Public Health policy. We must move toward a legal and regulatory environment in which clinical medicine is governed by empirical evidence and the literal text of the law, rather than by the algorithmic surveillance and extra-statutory inventions of an overreaching bureaucracy.
The impact of these legal proceedings on the “usual course of professional practice” has been catastrophic. The fear of prosecution has transformed clinical decision-making from a patient-centered model to a defensive, risk-avoidant model. Clinicians now operate under the constant threat that their adherence to medical standards will be reinterpreted as criminal activity by non-medical agency staff. This climate of fear has direct, fatal consequences for the patients these providers are sworn to protect.
THE HOLY TRINITY DISTORTION
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!
OUR TREE OF KNOWLEDGE SHALL NEVER BE SUPPRESSED
FOR NOW, YOU ARE WITHIN
THE NORMS
REFERENCES:
Pope Leo XIV’s pharmacological comprehension of the holy trinity
THE BIBLICAL INTERPRETATION OF THE HOLY TRINITY
On the Solemnity of the Most Holy Trinity, June 15, 2025, Pope Leo XIV described the Trinity as a dynamic communion of love—Father, Son, and Holy Spirit—that invites humanity into a relationship with God. Celebrating the Mass for the Jubilee of Sport, he emphasized that the divine life is a “dance of mutual love” and a model of unity.
Key themes from Pope Leo XIV’s discussion of the Holy Trinity include:
- Divine Love as Community: The Trinity is presented as a model of love and unity, with three persons living in deep, shared communion.
- Connection to Sport: In his homily, Pope Leo linked the Trinity to sports, describing both as activities that should encourage relationships, dialogue, and “giving of oneself” (gratuitousness).
- Reflecting God’s Image: He noted that humans, created in God’s image, are designed to reflect this love and to experience the “dynamic” of the divine inner life.
- Encouragement for Youth: Addressing young people, the Pope spoke of the Trinity as a source of strength and community during challenging times
